Mayo Clinic Laboratory and pathology research roundup: January 25 - Insights
Today's Topic Features: Measurable residual disease does not preclude prolonged progression-free survival in CLL treated with ibrutinib.
FDA Regulation of Laboratory Developed Tests - Insights
PACE/FL - This webinar will provide a brief history of the FDA’s interest in LDTs and review the new requirements in detail, serving as an introduction to medical device regulations in the context of a clinical laboratory.
Mayo Clinic Laboratory and Pathology Research Roundup: March 11 - Insights
This week’s Research Roundup highlights an assay to rapidly screen for immunoglobulin light chain glycosylation: a potential path to earlier AL diagnosis for a subset of patients and several other research articles by Mayo Clinic physicians...
Cytology Specimen Utilization: A Proven Approach to Genetic Sequencing - Insights
PACE / State of FL - Register now - May 21, 2025: - This webinar will explore the role of cytology specimens in molecular genetic testing, emphasizing their effectiveness in identifying biomarkers critical for targeted therapies in patients...
Activity Metrics Dashboard - Insights
We are excited to share that the Activity Metrics Dashboard is now live on mayocliniclabs.com. We heard your feedback and created these reports to provide a more integrated, intuitive and customized experience on our website.
Find out how our streamlined approach to fluorescence in situ hybridization testing can simplify the ordering process and better meet patient needs.
Making the Promise of AI a Reality in Laboratory Medicine and Pathology - Insights
Register now – June 26, 2025 PACE / State of FLThis webinar explores how artificial intelligence (AI) and digital pathology have the potential to revolutionize the clinical laboratory landscape. These technologies are transforming...
Linda Hasadsri, M.D., Ph.D., and Huong T. Cabral, M.S., C.G.C., explain how Mayo Clinic Laboratories' targeted test panel facilitates accurate diagnosis of hereditary pancreatitis, which heightens the risk for pancreatic cancer. Test...
Mayo Clinic Laboratories and KYAN Technologies announced a collaboration to validate and provide the KYAN test, Optim.AI™, across the United States.
Alicia Algeciras-Schimnich, Ph.D., discusses Mayo Clinic Laboratories’ new noninvasive plasma biomarker assay for Alzheimer’s disease, an accessible, highly accurate testing option for individuals age 50 and above who are experiencing mild...